Allarity Doses First Patients in VA-Funded Phase 2 Small Cell Lung Cancer Trial with Stenoparib and Temozolomide
Allarity has dosed the first patients with stenoparib plus temozolomide in a VA-funded Phase 2 trial enrolling at 11 VA centers for relapsed small cell lung cancer. Stenoparib’s dual PARP/WNT inhibition, blood–brain barrier penetration and favorable safety profile aim to enhance tolerability and efficacy in second-line SCLC.
1. Trial Launch and Dosing
Allarity has dosed the first patients with stenoparib and temozolomide in its investigator-initiated Phase 2 trial for relapsed small cell lung cancer. The study is open for enrollment at 11 Veterans Affairs medical centers nationwide.
2. Funding and Enrollment
The U.S. Department of Veterans Affairs fully funds the trial through its Special Emphasis Panel on Precision Oncology. This funding covers trial costs across all 11 VA sites, accelerating patient recruitment without direct company expenditure.
3. Dual Mechanism and Safety Profile
Stenoparib combines PARP1/2 and tankyrase 1/2 inhibition to disrupt DNA repair and WNT/β-catenin signaling, while crossing the blood–brain barrier. Its favorable hematologic safety profile may allow sustained combination with temozolomide, reducing dose-limiting toxicities seen with first-generation PARP inhibitors.
4. Unmet Need and Market Prospects
Over 26,000 Americans relapse with small cell lung cancer annually and only 40% receive second-line therapy for under two months on average. A well-tolerated, efficacious regimen could fill a significant treatment gap and underpin future commercial value for Allarity.